Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women"

Transcription

1 FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women Tze K. Lau, M.R.C.O.G.,* Din Wan, M.B., B.S.,* So F. Yim, M.R.C.O.G.,* John E. Sanderson, M.D., and Christopher J. Haines, M.D.,* The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong Objective: To investigate the effect of different types and methods of delivery of hormone replacement therapy (HRT) on peripheral vascular flow velocity in postmenopausal women. Design: A prospective, randomized, operator-blinded, controlled study. Setting: A hormone replacement clinic in a university teaching hospital. Patient(s): Sixty-eight women who had undergone surgical menopause. Intervention(s): No treatment, oral estrogen, continuous combined estrogen and progestogen, or percutaneous estrogen. Main Outcome Measure(s): The pulsatility indices of the brachial, dorsalis pedis, popliteal, and radial arteries were measured under standardized conditions before the commencement of HRT and after 2 and 6 months of treatment. Serum E 2 levels were measured at each visit. Result(s): There was an inverse correlation between the serum E 2 levels and the pulsatility indices. There was a significant reduction in the pulsatility index in at least one of the four arteries after 2 months of HRT in all the treatment groups but not in the control group. The effect of HRT on the pulsatility index persisted until the completion of the study in all the treatment groups. Conclusion(s): These results confirm that the administration of HRT is associated with a reduction of the pulsatility index, and hence an increase in blood flow in the peripheral arteries; this change in the pulsatility index is related directly to serum E 2 levels. The percutaneous route of administration of estrogen was at least as effective as oral treatment in improving peripheral vascular flow velocity. The beneficial effect of estrogen was not affected by the addition of a progestogen. (Fertil Steril 1998;70: by American Society for Reproductive Medicine.) Key Words: Hormone replacement therapy, peripheral artery, pulsatility index Received November 12, 1997; revised and accepted March 6, Supported by the Hong Kong Obstetrical and Gynaecological Trust Fund, Hong Kong. Reprint requests: Tze K. Lau, M.R.C.O.G., Department of Obstetrics and Gynaecology, The Prince of Wales Hospital, Shatin, New Territories, Hong Kong (FAX: ; * Department of Obstetrics and Gynaecology. Department of Medicine /98/$19.00 PII S (98) Menopause is associated with an increase in the incidence of cardiovascular disease (1), but this can be prevented in part by the administration of hormone replacement therapy (HRT) (2 4). Approximately one third of the cardioprotective effect of estrogen is thought to be due to beneficial changes in circulating lipids and lipoproteins (5). Another important mechanism is a direct effect of estrogen on blood vessels, where it has been shown to produce vasodilatation and improve blood flow. Several methods have been used to measure changes in blood flow after the administration of HRT, one of which is the measurement of the pulsatility index with the use of Doppler ultrasound (US). With this method, significant reductions in the pulsatility index have been observed in the internal carotid arteries (6, 7) and an increase in peak flow velocity has been found in the aorta (8). However, there is only limited information on the effect of HRT on the peripheral vessels, which are of smaller caliber and should reflect the behavior of resistance vessels better than the larger vessels previously studied (9). Almost all studies of the effect of estrogen on peripheral flow velocity have been conducted using oral estrogen. The use of percutaneous estrogen gels and transdermal patches are also popular methods of delivering estrogen for the purpose of HRT, but there is limited information regarding the effect of parenteral administration on flow velocity (9). Different 284

2 methods of delivery induce variable changes in the lipid profile (10), and this presumably is due to the hepatic firstpass effect. It is not known whether the route of administration of estrogen affects blood flow. Postmenopausal women who still have a uterus should receive a progestogen in addition to estrogen to prevent endometrial hyperplasia (11). The results of earlier studies suggested that the addition of a progestogen negated the beneficial effect of estrogen on lipids and lipoproteins, but several more recent reports have concluded that the use of the newer progestogens produces little effect on lipids (12), and continuous combined HRT appears to confer no deleterious effect on lipids and lipoproteins (13). Although progestogens have been investigated extensively with respect to the lipid profile, there is no information on whether progestogens influence the effect of estrogen on blood flow. In a previous small observational study, we found that the administration of oral estrogen with or without a progestogen was associated with a significant reduction in the pulsatility index in the peripheral arteries (14). However, this was a small pilot study in which there was no control group and no blinding. The aim of the present study was to substantiate the results of the original study. MATERIALS AND METHODS Study Design We conducted a prospective, randomized, operatorblinded, controlled study of the effect of HRT on the peripheral arteries in postmenopausal women. The study protocol was approved by the clinical research ethics committee of the local institution. Each subject was randomly allocated to one of four groups for a period of 6 months. Doppler US studies were performed at the time of recruitment and after 2 and 6 months of treatment. These periods were chosen as indicators of the acute and more prolonged effects of treatment. At the time of each flow study, blood was taken for the measurement of E 2. All subjects were referred back to the Hormone Replacement Clinic after the study for continuing care. Each group consisted of 17 patients. Based on the results of our previous study (14), the sample size calculation suggested that 8 patients were needed in each group to detect a mean ( SD) reduction in the pulsatility index with treatment of compared with a mean change of zero in the control group, with 80% power and an alpha error of An extra 9 patients in each group were recruited to overcome possible error in the assumptions used in the sample size calculation and to allow for dropouts. Wilcoxon s signed-rank test was used to examine the difference in the pulsatility index before and after treatment. The linear trend across different levels of serum E 2 (see later for details of categorization of E 2 level) was tested by the one-way analysis of variance (ANOVA). The Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL) was used for the analysis of all data. P.05 was considered statistically significant. Patients Patients were recruited from the Hormone Replacement Therapy Clinic of The Prince of Wales Hospital in Hong Kong. All patients newly referred to the clinic who had undergone surgical menopause were recruited. This included those who had undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for benign gynecologic conditions before natural menopause. We selected women who had undergone a hysterectomy to avoid the problem of bleeding with the use of unopposed estrogen. Exclusion criteria included [1] the use of any form of HRT in the preceding 3 months, [2] a history of hypertension or cardiovascular disease, [3] diabetes mellitus, [4] a contraindication to HRT, and [5] smoking. Written informed consent was provided by all patients who agreed to participate in the study. Treatment Plan The patients were assigned to one of four groups according to computer-generated random numbers. The treatment protocols were as follows: 1. No treatment (controls). 2. Oral E 2, 2 mg/d (Estrofem; Novo Nordisk, Bagsvaerd, Denmark). 3. Oral E 2, 2 mg/d, and norethisterone acetate, 1 mg/d (Kliogest; Novo Nordisk). 4. Percutaneous E 2, 2.5 g/d (Oestrogel; Besins-Iscovesco, Paris, France). Doppler Studies The peripheral arteries were studied using color duplex pulsed Doppler US (Aloka S-680) with a steered 7.5-MHz peripheral vascular US probe (Aloka UST ). All studies were performed by the same investigator in a quiet room with constant light and a room temperature between 21 C and 22 C. Patients fasted for at least 2 hours before the study and rested in a supine position for 15 minutes before any flow velocity measurements were taken. The follow-up studies were performed at a similar time of day as the initial studies, and the investigator who performed the flow studies was blinded to the treatment that the patients received. Before the study was initiated, the US equipment settings (including preprocessing, postprocessing, and sampling volume of the Doppler gate) were tested for each of the peripheral arteries to determine the optimal configuration for the examinations. The same settings then were used on each occasion for all patients. The pulsatility indices of four peripheral arteries on the right side of the body were examined using methods previously described (14). The pulsatility index is defined as (S-D)/A, where S is the peak systolic frequency shift, D is FERTILITY & STERILITY 285

3 TABLE 1 Characteristics at recruitment of 68 patients who had undergone surgical menopause. Characteristic No treatment (n 14) Oral estrogen (n 15) Combined estrogen and progestogen (n 13) Percutaneous estrogen (n 16) Age Duration of surgical menopause (y) Pulsatility index at recruitment Brachial artery Dorsalis pedis artery Popliteal artery Radial artery the end-diastolic frequency shift, and A is the temporal mean frequency shift over one cardiac cycle. The reproducibility of the Doppler measurements was tested before the commencement of the study. The investigator measured the pulsatility index of the brachial artery on a volunteer 10 times, 10 minutes apart, under the conditions described earlier. The mean ( SD) of the pulsatility index was (range, ). Serum E 2 Assessment The serum E 2 level was measured in all patients at each visit. A total of 259 samples were available and included both control and treated patients. Because of the limitation of the assay used, samples with E 2 levels of 90 pmol/l were reported as 90 pmol/l instead of as a numeric result. Therefore, E 2 concentrations were categorized into groups (e.g., 101 pmol/l, pmol/l, pmol/l) for subsequent analysis. RESULTS A total of 68 patients were recruited, with 17 in each study group. There were 4 dropouts, 1 from the control group, 2 from the continuous combined treatment group, and 1 from the percutaneous estrogen group. Each of these patients had completed only the first blood flow study. Five patients, 1 from the control group, 2 from the oral estrogen group, and 2 from the combined treatment group, were excluded from data analysis because their serum hormonal profiles at recruitment were not compatible with the menopausal state. One further patient from the control group was excluded because there was a substantial increase in the E 2 concentration (to 1,500 pmol/l) at the first follow-up visit, most likely due to the use of an exogenous supplement. There was no statistically significant difference between the four groups in age, duration of menopause, or the baseline pulsatility index of all four arteries studied at the time of recruitment (Table 1). Tables 2 and 3 show the difference in the pulsatility indices after 2 months and 6 months of treatment, respectively. There was an initial reduction in the pulsatility index in one or more arteries in all the treatment groups at the first follow-up study, but not in the control group. There was little change in the pulsatility index between 2 and 6 months of treatment. There were significant reductions in the pulsatility index in one or more arteries at TABLE 2 Paired difference in the pulsatility index after 2 months of hormone replacement therapy. Artery Brachial Dorsalis pedis Popliteal Radial Control (n 14) Oral estrogen (n 15) * * * Continuous combined estrogen and progestogen (n 13) * Percutaneous estrogen (n 16) * * * P.05 (versus pretreatment pulsatility index). 286 Lau et al. HRT and peripheral arterial flow Vol. 70, No. 2, August 1998

4 TABLE 3 Paired difference in the pulsatility index after 6 months of hormone replacement therapy. Artery Brachial Dorsalis pedis Popliteal Radial Control (n 14) Oral estrogen (n 15) * Continuous combined estrogen and progestogen (n 13) * Percutaneous estrogen (n 16) * * * * P.05 (versus pretreatment pulsatility index). 6 months compared with pretreatment measurements in all the treatment groups, but not in the control group. The reduction in the pulsatility index at 6 months was demonstrated in three of four arteries in the group that received percutaneous estrogen, but in only one of four arteries in the other treatment groups. There was a significant linear trend toward a lower pulsatility index with an increasing level of serum E 2 in three of the four arteries studied, namely the brachial artery (P.013), the dorsalis pedis artery (P.005), and the popliteal artery (P.001). An example using the dorsalis pedis artery is shown in Figure 1. The reduction in the pulsatility index appeared to be most FIGURE 1 Relation between the pulsatility index of the dorsalis pedis artery and different serum E 2 concentrations (total sample, n 259). There was a trend toward a lower pulsatility index with an increasing E 2 level (P.005, ANOVA with linear trend). Solid circles represent means, with 95% confidence interval represented by the bars. profound after 2 months of treatment, because there was a significant reduction in the pulsatility index in three of the four arteries after 2 months of treatment compared with only one of the four arteries after 6 months of treatment. In contrast, the reduction in the pulsatility index appeared to be most profound after 6 months of treatment among those who received percutaneous estrogen. DISCUSSION This is the first randomized study on the effect of HRT on peripheral vascular flow. Previous observational studies have demonstrated a beneficial effect on the Doppler parameters of the central arteries after HRT in postmenopausal women, with either a reduction in the pulsatility index or an increase in peak flow velocity (6 8). Gilligan et al. (9) reported an improvement in endothelial function in the peripheral blood vessels after the acute intra-arterial administration of E 2. However, in most of these studies, there was a lack of controls and measurement bias could not be excluded because the treatment the patients received was known to the operator. The pulsatility index is an indirect measurement of the vascular resistance and therefore of blood flow (15). To minimize errors in Doppler examinations, all measurements in this study were performed under standard conditions and environments by one operator, in whom the intra-observer error of measurement had been found to be only 4.6%. We found that there was a significant reduction in the pulsatility index after 2 months of treatment in at least one vessel in all the patients who received HRT, but not in the control patients. Similar results were obtained after 6 months of treatment. However, the reduction in the pulsatility index after 2 months was most convincing with oral treatment, as significant changes were demonstrated in three of four vessels, compared with only one of four vessels with continuous combined or percutaneous treatment. After 6 months, however, there were significant reductions in the pulsatility index in three of four vessels with percutaneous estrogen, but in FERTILITY & STERILITY 287

5 only one vessel with the other treatment regimens. It thus appeared that oral HRT had a more profound short-term effect on the peripheral arteries. The difficulties involved in conducting these studies did not allow for a definite conclusion regarding whether percutaneous treatment confers the greatest long-term benefit, although this appears to be the case. The level of E 2 correlated negatively with the pulsatility index, and this suggests that the concentration of circulating E 2 is a major determinant of the reduction in the pulsatility index regardless of the route of administration of treatment. To our knowledge, this is the first study to investigate the effect of the different methods of estrogen administration on peripheral vascular flow velocity. Estrogen receptors have been reported to be present in the vessel wall (16), and E 2 can initiate the release of nitric oxide, a potent vasodilator (17). We demonstrated that the percutaneous method of treatment is at least as effective as oral therapy. Our results also support the hypothesis that estrogen replacement acts directly on the vessel wall and causes vasodilatation. The effect of the addition of progestogen also was studied. Reductions in the pulsatility index were found in at least one vessel at both 2 and 6 months in patients who received continuous combined HRT. At 6 months, the magnitude of the reduction was similar to that observed with the use of unopposed estrogen, suggesting that the addition of the progestogen does not significantly affect the blood flow increase in response to oral estrogen treatment. We conclude that HRT is associated with a reduction in the pulsatility index of the peripheral arteries, which may represent a direct vasodilator effect of estrogen on the peripheral vasculature. This change appears to take place regardless of the route of administration of estrogen and does not appear to be influenced by the addition of a progestogen. References 1. Sarrel PM. Ovarian hormones and the circulation. Maturitas 1990;12: Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117: Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991;325: Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75: Orimo A, Inoue S, Ikegami A, Hosoi T, Akishita M, Ouchi Y, et al. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun 1993;195: Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991;338: Penotti M, Nencioni T, Gabrielli L, Farina M, Castiglioni E, Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1993;169: Pines A, Fisman EZ, Levo Y, Averbuch M, Lidor A, Drory Y, et al. The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol 1991;164: Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon III RO. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75: Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166: Paterson M, Wade-Evans T, Sturdee DW, Thom MH, Studd JWW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980;280: Lobo AL, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84: Writing Group for PEPI Trial: Effects of estrogens or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin trial. JAMA 1995;273: Lau TK, Chung TKH, Haines CJ. A preliminary study on the effect of hormone replacement therapy on peripheral flow velocity in postmenopausal women. Maturitas 1997;26: Woodcock JP, Gosling RG, Fitzgerald DE. A new noninvasive technique for assessment of superficial femoral arterial obstruction. Br J Surg 1972;59: Lin AL, Shain SA. Estrogen-mediated cytoplasmic and nuclear distribution of rat cardiovascular estrogen receptors. Arteriosclerosis 1985; 5: Gislard V, Millar V, Van Houte P. Effects of 17 -oestradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988;244: Lau et al. HRT and peripheral arterial flow Vol. 70, No. 2, August 1998

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003 HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College

More information

Postmenopausal hormones and coronary artery disease: potential benefits and risks

Postmenopausal hormones and coronary artery disease: potential benefits and risks CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,

More information

A double-blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index

A double-blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index British Journal of Obstetrics and Gynaecology April 1998, Vol. 105, pp. 408412 A double-blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index

More information

Low & Ultra Low Dose HRT The Cardiovascular Impact

Low & Ultra Low Dose HRT The Cardiovascular Impact Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior

More information

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College

More information

Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women

Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2015;21:104-111 Original Article Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women Jee-Yeon Lee, Hye

More information

CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY

CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY Biomed. Papers 147(2), 211 219 (2003) D. Houserková, J. Matlochová, M. Hartlová 211 CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY Dana Houserková

More information

Copyright, 1995, by the Massachusetts Medical Society

Copyright, 1995, by the Massachusetts Medical Society Copyright, 1995, by the Massachusetts Medical Society Volume 332 JUNE 15, 1995 Number 24 THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN GRAHAM A. COLDITZ, M.B.,

More information

Premenopausal women have a lower cardiovascular

Premenopausal women have a lower cardiovascular AJH 1998;11:1147 1152 Ambulatory Not Office Blood Pressures Decline During Hormone Replacement Therapy in Healthy Postmenopausal Women Frans J. van Ittersum, W. Marchien van Baal, Peter Kenemans, Velja

More information

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR

More information

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

Endometrial blood flow response to hormone replacement therapy in women with premature ovarian failure: a transvaginal Doppler study

Endometrial blood flow response to hormone replacement therapy in women with premature ovarian failure: a transvaginal Doppler study . M.,nopause FERTILITY AND STERILITY Vol. 63, No.3, March 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. s. A. Endometrial blood flow response to hormone

More information

Postmenopausal hormone therapy and cancer risk

Postmenopausal hormone therapy and cancer risk International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation

More information

Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure

Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure The Journal of International Medical Research 2007; 35: 416 421 Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2,

More information

A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study

A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study BJOG: an International Journal of Obstetrics and Gynaecology September 2002, Vol. 109, pp. 1056 1062 A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth

More information

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus) HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric

More information

AusPharm CE Hormone therapy 23/09/10. Hormone therapy

AusPharm CE Hormone therapy 23/09/10. Hormone therapy Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of

More information

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes* FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term

More information

P remenopausal women have a lower risk of coronary

P remenopausal women have a lower risk of coronary 777 CARDIOVASCULAR MEDICINE Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction I N Alecrin,

More information

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY

More information

Journal of the American College of Cardiology Vol. 38, No. 7, by the American College of Cardiology ISSN /01/$20.

Journal of the American College of Cardiology Vol. 38, No. 7, by the American College of Cardiology ISSN /01/$20. Journal of the American College of Cardiology Vol. 38, No. 7, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01658-8 Modulation

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years

More information

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,

More information

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased

More information

Research. Breast cancer represents a major

Research. Breast cancer represents a major Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.

More information

Arterial stiffness is not improved in long-term use of estrogen

Arterial stiffness is not improved in long-term use of estrogen Arterial stiffness is not improved in long-term use of estrogen Kenny A. Rodriguez-Macias, MD, a Tord Naessen, MD, PhD, a Annika Boström, MD, b and David Bergqvist, MD, PhD b Uppsala, Sweden OBJECTIVE:

More information

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence: Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion

More information

Postmenopausal hormone therapy - cardiac disease risks and benefits

Postmenopausal hormone therapy - cardiac disease risks and benefits Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting

More information

Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study

Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study European Journal of Endocrinology (2006) 154 101 107 ISSN 0804-4643 CLINICAL STUDY Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention

More information

Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study

Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study European Journal of Endocrinology (2006) 154 101 107 ISSN 0804-4643 CLINICAL STUDY Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention

More information

Does female gender or hormone replacement therapy affect early or late outcome after carotid endarterectomy?

Does female gender or hormone replacement therapy affect early or late outcome after carotid endarterectomy? Does female gender or hormone replacement therapy affect early or late outcome after carotid endarterectomy? John S. Lane, MD, a Shant Shekherdimian, BS, b and Wesley S. Moore, MD, b Francisco, Calif Los

More information

Vascular Sonography Examination

Vascular Sonography Examination Vascular Sonography Examination The purpose of The American Registry of Radiologic Technologists (ARRT ) Vascular Sonography Examination is to assess the knowledge and cognitive skills underlying the intelligent

More information

Risk-reducing surgery and hormones

Risk-reducing surgery and hormones Risk-reducing surgery and hormones Nora Johansen Registrar and PhD student at Department of Obstetrics and Gynecology, Sørlandet Hospital Arendal, Norway No conflicts of interest to declare Overview Hereditary

More information

HRT, breast and endometrial cancers: strategies and intervention options

HRT, breast and endometrial cancers: strategies and intervention options Maturitas 32 (1999) 131 139 www.elsevier.com/locate/maturitas HRT, breast and endometrial cancers: strategies and intervention options Piero Sismondi a, *, Nicoletta Biglia a, Maurizia Giai a, Riccardo

More information

Acute Vascular Effects of Estrogen

Acute Vascular Effects of Estrogen 786 Acute Vascular Effects of Estrogen in Postmenopausal Women David M. Gilligan, MD; Diane M. Badar, RN; Julio A. Panza, MD; Arshed A. Quyyumi, MD; Richard. Cannon III, MD Downloaded from http://ahajournals.org

More information

Artery 1 Head and Thoracic Arteries. Arrange the parts in the order blood flows through them.

Artery 1 Head and Thoracic Arteries. Arrange the parts in the order blood flows through them. Artery 1 Head and Thoracic Arteries 1. Given the following parts of the aorta: 1. abdominal aorta 2. aortic arch 3. ascending aorta 4. thoracic aorta Arrange the parts in the order blood flows through

More information

Lipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob

Lipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob Lipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob Abstract Background: Dyslipidemia is a major cause of cardiovascular

More information

Financial Conflicts of Interest

Financial Conflicts of Interest Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine

More information

Hormonal Therapy Increases Arterial Compliance in Postmenopausal Women

Hormonal Therapy Increases Arterial Compliance in Postmenopausal Women 350 JACC Vol. 30, No. 2 ATHEROSCLEROSIS Hormonal Increases Arterial Compliance in Postmenopausal Women CHAKRAVARTHI RAJKUMAR, MD, BRONWYN A. KINGWELL, PHD, JAMES D. CAMERON, MD, MENGSC,* TAMARA WADDELL,

More information

The Fetus: Five Top Do Not Miss Diagnoses. Doppler Ultrasound

The Fetus: Five Top Do Not Miss Diagnoses. Doppler Ultrasound The Fetus: Five Top Do Not Miss Diagnoses Doppler Ultrasound Giancarlo Mari, MD, MBA Professor and Chair Department of Obstetrics and Gynecology University of Tennessee Health Science Center Memphis, TN

More information

Discussing breast cancer and hormone replacement therapy with women

Discussing breast cancer and hormone replacement therapy with women INTERPRETING KEY TRIALS PELIN BATUR, MD Section of Women s Health, Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic HOLLY L. THACKER, MD, FACP Departments

More information

Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece

Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece Dimitrios Terentes-Printzios, Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Mahmoud Abdelrasoul,

More information

APPLICATION OF PHYSICAL METHODS FOR DETERMINATION OF FUNCTIONAL PARAMETERS OF ARTERIES IN RHEUMATIC PATIENTS

APPLICATION OF PHYSICAL METHODS FOR DETERMINATION OF FUNCTIONAL PARAMETERS OF ARTERIES IN RHEUMATIC PATIENTS APPLICATION OF PHYSICAL METHODS FOR DETERMINATION OF FUNCTIONAL PARAMETERS OF ARTERIES IN RHEUMATIC PATIENTS Jolanta DADONIENE*, Alma CYPIENE**, Diana KARPEC***, Rita RUGIENE*, Sigita STROPUVIENE*, Aleksandras

More information

Sex, hormones and the heart

Sex, hormones and the heart Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards

More information

Effects of a short-term suspension of hormone replacement therapy on mammographic density

Effects of a short-term suspension of hormone replacement therapy on mammographic density FERTILITY AND STERILITY VOL. 76, NO. 3, SEPTEMBER 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of a short-term

More information

Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy

Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy l FERTLTY AND STERLTY Vol. 62, 6, December 1994 Copyright e 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Endometrial ablation for refractory postmenopausal bleeding with continuous

More information

Haemostasis, thrombosis risk and hormone replacement therapy

Haemostasis, thrombosis risk and hormone replacement therapy Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis

More information

An Evidence-based Review of Clinical Trial Data

An Evidence-based Review of Clinical Trial Data An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data

More information

CY Tse, AMK Chow, SCS Chan. Introduction

CY Tse, AMK Chow, SCS Chan. Introduction Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate

More information

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference

More information

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and

More information

The relative effects of progesterone and progestins in hormone replacement therapy

The relative effects of progesterone and progestins in hormone replacement therapy Human Reproduction, Vol. 15, (Suppl. 1), pp. 60-73, 2000 The relative effects of progesterone and progestins in hormone replacement therapy G.M.C.Rosano 1 ' 3, C.Sarais 2, S.Zoncu 2 and G.Mercuro 2 'Department

More information

STRUCTURED EDUCATION REQUIREMENTS IMPLEMENTATION DATE: JULY 1, 2016

STRUCTURED EDUCATION REQUIREMENTS IMPLEMENTATION DATE: JULY 1, 2016 STRUCTURED EDUCATION REQUIREMENTS Vascular Sonography The purpose of structured education is to provide the opportunity for individuals to develop mastery of discipline-specific knowledge that, when coupled

More information

Sympathetic Vasomotor Response Of The Radial Artery In Patients With End Stage Renal Disease

Sympathetic Vasomotor Response Of The Radial Artery In Patients With End Stage Renal Disease ISPUB.COM The Internet Journal of Nephrology Volume 2 Number 1 Sympathetic Vasomotor Response Of The Radial Artery In Patients With End Stage Renal Disease L Galea, M Schembri, M Debono Citation L Galea,

More information

Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial

Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial DOI: 10.1111/1471-0528.12598 www.bjog.org Epidemiology Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial

More information

The Practice Committee of the American Society for Reproductive Medicine,

The Practice Committee of the American Society for Reproductive Medicine, FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen

More information

Ali Serdar Fak, M.D.,* Mithat Erenus, M.D., Hakan Tezcan, M.D.,* Oguz Caymaz, M.D.,* Sule Oktay, M.D., Ph.D., and Ahmet Oktay, M.D.

Ali Serdar Fak, M.D.,* Mithat Erenus, M.D., Hakan Tezcan, M.D.,* Oguz Caymaz, M.D.,* Sule Oktay, M.D., Ph.D., and Ahmet Oktay, M.D. FERTILITY AND STERILITY VOL. 73, NO. 1, JANUARY 2000 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of a single

More information

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology

More information

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,

More information

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 550 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion 4.1.1 Humans The pharmacokinetics of the newer progestogens, desogestrel,

More information

Appendix H: Evidence on HRT and Gallbladder Disease H

Appendix H: Evidence on HRT and Gallbladder Disease H Appendix H: Evidence on HRT and Gallbladder Disease H T here are several theoretical reasons to expect a causal link between estrogens and gallbladder disease. In particular, estrogens increase the risk

More information

Hormone therapy (HT) is one ABSTRACT WOMEN S HEALTH. Current Status of Postmenopausal Hormone Therapy. Mary S. Beattie, MD

Hormone therapy (HT) is one ABSTRACT WOMEN S HEALTH. Current Status of Postmenopausal Hormone Therapy. Mary S. Beattie, MD Current Status of Postmenopausal Hormone Therapy Mary S. Beattie, MD ABSTRACT Estrogen therapy, with or without progestins, has been widely prescribed for the treatment of menopausal symptoms. However,

More information

Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes

Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998

More information

New products and regimens (since 2003)

New products and regimens (since 2003) CLIMACTERIC 2007;10(Suppl 2):109 114 New products and regimens (since 2003) N. West London Menopause & PMS Centre, London, UK Key words: HORMONE REPLACEMENT THERAPY, ULTRA-LOW-DOSE THERAPY, TRANSDERMAL

More information

From the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland

From the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland Acta Obstet Gynecol Scand 2000; 79: 1029 1036 Copyright C Acta Obstet Gynecol Scand 2000 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 OPINION Balancing

More information

Radiologic Evaluation of Peripheral Arterial Disease

Radiologic Evaluation of Peripheral Arterial Disease January 2003 Radiologic Evaluation of Peripheral Arterial Disease Grace Tye, Harvard Medical School Year III Patient D.M. CC: 44 y/o male with pain in his buttocks Occurs after walking 2 blocks. Pain is

More information

For more than 50 million American women, and millions

For more than 50 million American women, and millions AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.

More information

Orals,Transdermals, and Other Estrogens in the Perimenopause

Orals,Transdermals, and Other Estrogens in the Perimenopause Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter

More information

An Indian Journal FULL PAPER ABSTRACT KEYWORDS. Trade Science Inc.

An Indian Journal FULL PAPER ABSTRACT KEYWORDS. Trade Science Inc. [Type text] [Type text] [Type text] ISSN : 0974-7435 Volume 10 Issue 16 BioTechnology 2014 An Indian Journal FULL PAPER BTAIJ, 10(16), 2014 [8944-8948] Clinical study on the relationship between blood

More information

Change in Elasticity Caused by Flow-Mediated Dilation Measured Only for Intima Media Region of Brachial Artery

Change in Elasticity Caused by Flow-Mediated Dilation Measured Only for Intima Media Region of Brachial Artery Japanese Journal of Applied Physics Vol. 44, No. 8, 25, pp. 6297 631 #25 The Japan Society of Applied Physics Change in Elasticity Caused by Flow-Mediated Dilation Measured Only for Intima Media Region

More information

Image Formation (10) 2 Evaluation and Selection of Representative Images (10)

Image Formation (10) 2 Evaluation and Selection of Representative Images (10) STRUCTURED SELF ASSESSMENT CONTENT SPECIFICATIONS SSA LAUNCH DATE: JANUARY 1, 2018 Vascular Sonography The purpose of continuing qualifications requirements (CQR) is to assist registered technologists

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

See page 138 OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS

See page 138 OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS Journal of the American College of Cardiology Vol. 34, No. 1, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00155-2 Hormone

More information

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,

More information

3/10/2009 VESSELS PHYSIOLOGY D.HAMMOUDI.MD. Palpated Pulse. Figure 19.11

3/10/2009 VESSELS PHYSIOLOGY D.HAMMOUDI.MD. Palpated Pulse. Figure 19.11 VESSELS PHYSIOLOGY D.HAMMOUDI.MD Palpated Pulse Figure 19.11 1 shows the common sites where the pulse is felt. 1. Temporal artery at the temple above and to the outer side of the eye 2. External maxillary

More information

One of the commonest gynecological cancers,especially in white Americans.

One of the commonest gynecological cancers,especially in white Americans. Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in

More information

Said Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Said Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt ARC Journal of Gynecology and Obstetrics Volume 1, Issue 2, 2016, PP 7-12 ISSN No. (Online) 2456-0561 http://dx.doi.org/10.20431/2456-0561.0102003 www.arcjournals.org Efficacy and Acceptability of two

More information

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure 801 Original Article Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure Akira YAMASHINA, Hirofumi TOMIYAMA, Tomio ARAI, Yutaka KOJI, Minoru YAMBE, Hiroaki MOTOBE, Zydem

More information

Estrogen and progestogen therapy in postmenopausal women

Estrogen and progestogen therapy in postmenopausal women Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone

More information

Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy

Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy European Heart Journal (1996) 17 {Supplement D), 9-14 Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy T. L. Bush The increasing use

More information

The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal Women

The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal Women Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed

More information

Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women

Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women European Heart Journal (1996) 17 {Supplement D), 32-37 Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women J. M. Sullivan University of Tennessee, Memphis, TN,

More information

Natural Hormones Replacement An Evidence and Practice Based Approach

Natural Hormones Replacement An Evidence and Practice Based Approach Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS

More information

EVALUATION OF NONINVASIVE PULSE TRANSIT TIME METHODOLOGIES FOR DIAGNOSIS OF HYPERTENSION DANIEL JOHN BADGER. A thesis submitted to the

EVALUATION OF NONINVASIVE PULSE TRANSIT TIME METHODOLOGIES FOR DIAGNOSIS OF HYPERTENSION DANIEL JOHN BADGER. A thesis submitted to the EVALUATION OF NONINVASIVE PULSE TRANSIT TIME METHODOLOGIES FOR DIAGNOSIS OF HYPERTENSION by DANIEL JOHN BADGER A thesis submitted to the Graduate School-New Brunswick Rutgers, The State University of New

More information

QUERIES: to be answered by AUTHOR

QUERIES: to be answered by AUTHOR Manuscript Information Climacteric Journal Acronym Volume and issue Author name Manuscript No. (if applicable) DCLI _A_254789 Typeset by KnowledgeWorks Global Ltd. for QUERIES: to be answered by AUTHOR

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease (2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk

More information

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,

More information

Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List

Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Practical recommendations for hormone replacement therapy in the peri- and postmenopause

Practical recommendations for hormone replacement therapy in the peri- and postmenopause CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David

More information